FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

FDA’s approval late Friday of Abecma idecabtagene vicleucel marks the second CAR T cell therapy BMS will bring to market as it continues to fill out its cancer portfolio ahead of revenue losses from upcoming patent cliffs. 

Patent expirations for the pharma’s top three sellers — Revlimid lenalidomide, Eliquis apixaban and Opdivo nivolumab — begin between one and eight years from now. Together, the three drugs accounted for over $28 billion, or two-thirds, of its global 2020 sales. ...